Nuvation Bio CFO exercises options for 40,000 shares

Nuvation Bio Inc. reports that Chief Financial Officer Philippe Sauvage exercised employee stock options covering 40,000 shares of Class A common stock on July 15, 2026 through two transactions at exercise prices of $1.97 and $2.17 per share.

Rhea-AI Filing Summary

Nuvation Bio Inc. reports that Chief Financial Officer Philippe Sauvage exercised employee stock options covering 40,000 shares of Class A common stock on July 15, 2026 through two transactions at exercise prices of $1.97 and $2.17 per share. Corresponding option positions were reduced, while the acquired shares are held directly. Footnotes state that the reported common share balance includes 1,458 shares purchased through the employee stock purchase plan on May 19, 2026, and describe option grants that vest 25% on the one-year anniversaries of October 7, 2024 and February 28, 2025 and monthly over the following 36 months, subject to continued service.

Insider Trade Summary

40,000 shares exercised/converted

Exercise 4 txns

Insider Sauvage Philippe

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F2	39,999	$0.00	$0.00
Exercise	Stock Option (Right to Buy) F3	1	$0.00	$0.00
Exercise	Class A Common Stock F1	39,999	$2.17	$87K
Exercise	Class A Common Stock F1	1	$1.97	$1.97

Holdings After Transaction: Stock Option (Right to Buy) — 1,162,332 contracts (Direct); Class A Common Stock — 54,131 shares (Direct)

Footnotes (3)

1. F1. Includes 1,458 shares purchased through the issuer's employee stock purchase plan on May 19, 2026.
2. F2. Option vests as to 25% on the one year anniversary of October 7, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.
3. F3. Option vests as to 25% on the one year anniversary of February 28, 2025, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

Key Figures

Shares acquired via option exercise: 40,000 shares Exercise price (grant 1): $1.97 per share Exercise price (grant 2): $2.17 per share +4 more

7 metrics

Shares acquired via option exercise 40,000 shares Total Class A common shares underlying options exercised on July 15, 2026

Exercise price (grant 1) $1.97 per share Exercise price for 1 share of Class A common stock

Exercise price (grant 2) $2.17 per share Exercise price for 39,999 shares of Class A common stock

Remaining options at $1.97 499,999 options Stock options (right to buy) remaining after the $1.97 exercise

Remaining options at $2.17 662,333 options Stock options (right to buy) remaining after the $2.17 exercise

Option expiration dates 2035-02-27 and 2034-10-06 Expiration dates for the two option grants exercised in part

ESPP shares included 1,458 shares Shares purchased via employee stock purchase plan on May 19, 2026

Key Terms

Stock Option (Right to Buy), employee stock purchase plan, Class A Common Stock, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

employee stock purchase plan financial

"Includes 1,458 shares purchased through the issuer's employee stock purchase plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Class A Common Stock financial

"security_title: "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

vesting financial

"Option vests as to 25% on the one year anniversary ... and monthly thereafter"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: "2035-02-27" and "2034-10-06" for option grants"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nuvation Bio (NUVB) CFO Philippe Sauvage report in this Form 4?

CFO Philippe Sauvage reported exercising employee stock options for 40,000 shares of Nuvation Bio Class A common stock on July 15, 2026, at exercise prices of $1.97 and $2.17 per share, increasing his directly held shares.

How many Nuvation Bio (NUVB) shares did the CFO acquire and at what prices?

The CFO acquired 40,000 shares of Nuvation Bio Class A common stock via option exercises. One transaction covered 1 share at $1.97 per share and another covered 39,999 shares at $2.17 per share, according to the filing data.

Were any Nuvation Bio (NUVB) shares sold in this CFO Form 4 filing?

No common shares were reported as sold. The Form 4 shows the CFO exercised stock options to acquire 40,000 Class A common shares, with matching reductions in the related option positions, but no sale transactions in the company’s stock.

What stock options remain for the Nuvation Bio (NUVB) CFO after these exercises?

After these transactions, one option grant shows 499,999 options remaining at a $1.97 exercise price, and another shows 662,333 options remaining at a $2.17 exercise price, each expiring in 2035 and 2034, respectively.

What do the vesting footnotes in the Nuvation Bio (NUVB) Form 4 indicate?

Footnotes state two option grants vest 25% on the one-year anniversaries of October 7, 2024 and February 28, 2025, then vest monthly over the following 36 months, contingent on the CFO’s continuous service with the company.

How many Nuvation Bio (NUVB) shares were bought through the employee stock purchase plan?

A footnote explains that the reported share balance includes 1,458 shares acquired through Nuvation Bio’s employee stock purchase plan on May 19, 2026, in addition to shares obtained via stock option exercises.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 06:27 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sauvage Philippe

(Last) (First) (Middle)

C/O NUVATION BIO INC.

1500 BROADWAY, SUITE 1401

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	07/15/2026		M		39,999	A	$2.17	54,130(1)	D
Class A Common Stock	07/15/2026		M		1	A	$1.97	54,131(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.17	07/15/2026		M			39,999	(2)	10/06/2034	Class A Common Stock	39,999	$0	662,333	D
Stock Option (Right to Buy)	$1.97	07/15/2026		M			1	(3)	02/27/2035	Class A Common Stock	1	$0	499,999	D

Explanation of Responses:

1. Includes 1,458 shares purchased through the issuer's employee stock purchase plan on May 19, 2026.

2. Option vests as to 25% on the one year anniversary of October 7, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

3. Option vests as to 25% on the one year anniversary of February 28, 2025, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

	/s/ Stephen Dang, Attorney-in-Fact, Attorney-in-Fact	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)